Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Transcriptional suppression of innate immunity by chimeric transcription factors

Award Number: R01CA300571
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/13/2026
PERIOD OF PERFORMANCE END DATE: 02/28/2031

Group Awards By:

View Award Description

Transcriptional suppression of innate immunity by chimeric transcription factors - ABSTRACT Immunosurveillance silencing by oncoproteins promotes tumor progression and immunotherapy evasion. However, little is known about the immunosuppression by chimeric transcription factors, drivers of many cancers such as alveolar rhabdomyosarcoma (aRMS). aRMS is an aggressive childhood soft tissue sarcoma mainly driven by the pathognomonic fusion oncoprotein PAX3–FOXO1 (or its variant PAX7–FOXO1). Chimeric transcription factors including PAX3/7-FOXO1 are notoriously difficult to target. Even with intensive chemotherapy and radiotherapy, the 5-year survival for the fusion-positive aRMS remains poor. No significant improvement has been made toward curing aRMS in decades, underscoring an urgent need to better understand the biology of PAX3/7-FOXO1 for developing more effective therapies. Our unpublished preliminary study indicates that PAX3-FOXO1 is involved in suppressing cancer cell-intrinsic immune response in aRMS cells. When the cancer cell-intrinsic immunosuppression is re-activated, potent anti-tumor activity is induced. These data led us to propose a novel hypothesis that PAX3/7–FOXO1 suppress the intrinsic innate immunity typified by type I interferon response through transcriptionally silencing cytosolic RNA and DNA sensing pathways, which can be leveraged to new immunotherapies. To test this hypothesis, we propose the following two Specific Aims: (1) To investigate the underlying mechanism of dsRNA sensing silenced by PAX3/7-FOXO1 (Aim 1); (2) To investigate the underlying mechanism of cytosolic DNA sensing silenced by PAX3/7–FOXO1 (Aim 2). This innovative study is to determine an unprecedent mechanism by which a chimeric transcription factor inhibits intrinsic type I interferon response by simultaneously suppressing the cytosolic RNA and DNA sensing pathways. The proposed research has translational relevance for children with high-risk aRMS as well as the potential to shed light on the molecular mechanisms of PAX3/7–FOXO1-driven aRMS and other cancers driven by chimeric transcription factors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $617,486 )
2026	2026	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Cancer Cause and Prevention Research	000	1	3/13/2026	NEW	$617,486
														Subtotal = $617,486

Grand Total All Awards = $617,486

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Transcriptional suppression of innate immunity by chimeric transcription factors

Award Number: R01CA300571

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/13/2026

PERIOD OF PERFORMANCE END DATE: 02/28/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer